[Nebulizing terbutaline therapy in children with acute asthma].
To evaluate the therapeutic effect of nebulized terbutaline in children with acute asthma, 21 children, aged 1 year and 7 months to 10 years, with acute asthma, were enrolled into this study, during the period from July to December 1989. Each patient received nebulized terbutaline (Bricanyl) 5 mg/dose over 10 minutes. The respiratory rate, pulse rate, blood pressure, peak expiratory flow rate and clinical severity score were recorded before, and at 10 minutes after treatment. Comparing with the data before treatment, respiratory rate, peak expiratory flow rate and clinical severity score at 10 minutes after treatment showed significant improvement (p value less than 0.05; less than 0.0005; less than 0.0001, respectively), but pulse rate and blood pressure did not differ significantly. It was concluded that administration of nebulized terbutaline, at a dose of 5 mg, was both safe and effective in treating acute asthma, and may be used as the first line measure in treating acute asthma in children.
Lee
B F
BF
Department of Pediatrics, Taipei Municipal Chung-Hsiao Hospital, Taiwan, R.O.C.
Lin
Y Z
YZ
Chen
W
W
Wu
K W
KW
D000208:Acute Disease; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008168:Lung / Q000503:physiopathology; D008297:Male; D009330:Nebulizers and Vaporizers; D013726:Terbutaline / Q000008:administration & dosage*
D013726:Terbutaline